AI-generated analysis. Always verify with the original filing.
Pacific Biosciences of California, Inc. announced Q4 and full year 2025 financial results on February 12, 2026, reporting Q4 revenue of $44.6 million (up 14% YoY) and full year revenue of $160.0 million, with record consumables revenue and strengthened balance sheet from $48.1 million short-read asset sale.
Event Type
Disclosure
Mandatory
Variant
8-K
). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934
. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release dated February 1 2 , 202 6 , titled “PacBio Announces Fourth Quarter and F ul l Year 202 5
| Metric | Value | Basis |
|---|---|---|
| Revenue | $44.60 | |
| Consumable revenue | $21.60 | |
| Instrument revenue | $17.30 | |
| Service and other revenue | $5.70 | |
| GAAP Gross profit | $16.60 | GAAP |
| Non-GAAP Gross profit | $17.80 | Non-GAAP |
| Non-GAAP gross margin | 40% | Non-GAAP |
| GAAP operating expenses | $57.80 | GAAP |
| Non-GAAP operating expenses | $56.20 | Non-GAAP |
| GAAP net loss | $-40.40 | GAAP |
| GAAP basic net loss per share | $-0.13 | GAAP |
| Non-GAAP net loss | $-37.60 | Non-GAAP |
| Non-GAAP basic net loss per share | $-0.12 | Non-GAAP |